Aim: Monascin and ankaflavin, the major fractions of the fungal-derived monascus yellow pigments, were incorporated with the herbal drug, resveratrol (RSV) within the core of folate-conjugated casein micelles (FA-CAS MCs, F1) for active targeting. PEGylated RSV-phospholipid complex bilayer enveloping caseinloaded micelles (PEGPC-CAS MCs) were also developed as passive-targeted nanosystem.Results: FA-and PEGPC-CAS MCs demonstrated a proper size with monomodal distribution, sustained drug release profiles and good hemocompatibility. The coloaded MCs showed superior cytotoxicity to MCF-7 breast cancer cells compared with free drugs. Both nanosystems exerted excellent in vivo antitumor efficacy in breast cancer bearing mice with PEGylated MCs showing comparable tumor regression to folate-conjugated MCs. Conclusion: Evergreen nanoplatforms coloaded with monascus yellow pigments and RSV were effective for breast cancer treatment. Searching behind nature by the aid of nanobiotechnological approaches represented a powerful strategy in cancer treatment by improving the efficacy of antineoplastic drugs along with reducing their side effects. Throughout the ages, humans have depended on nature to acquire their principle requirements [1] [2] [3] . Resveratrol (RSV) is one of the most appealing natural phytoalexin antineoplastic drugs by virtue of its apoptotic, antiangiogenesis and aromatase inhibition effect [4] . RSV inhibited the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and regulates cell differentiation, growth and proliferation. It is a potent sensitizer that affects several mechanisms involved in carcinogenesis (e.g., p53, NF-kB, PKC and cyclooxygenases [COX]) [5] .
Despite their highly hydrophobic nature resulting in poor bioavailability, there were no reports about delivery systems for MNS and ANK. Similarly, the low aqueous solubility of RSV is perceived as a major hindrance in its potential medical application for cancer management. Polymeric micelles (MCs) hold great promise by entrapping lipophilic agents in their hydrophobic core [11] [12] [13] . Casein (CAS), the main milk protein, demonstrated amphiphilic nature being composed of both hydrophobic and hydrophilic amino acids. Thus, it is capable to self-assemble into spherical MCs [14, 15] .
A fundamental drawback for cancer treatment is its nonselective nature to such tumor cells. Hence, inducing uptake selectivity in tumor site by targeted delivery of the drugs acquired a significant value in cancer therapy [16] . The overexpression of certain receptors on cancer cell surface (e.g., folic acid [FA] receptors) represented a key factor in cancer processes such as tumor invasion, metastasis, recurrence and chemoresistance. FA-conjugated protein-polyelectrolyte complex for targeted delivery of 5-fluorouracil against MCF-7 and MDA-MB-231 cells was prepared by Anirudhan and Christa for targeting overexpressed folate receptors by tumor cells [17, 18] .
Nanophytomedicine approach could improve the bioavailability and efficacy of several herbal components. Green select phytosome, a lecithin formulation of a caffeine-free green tea catechin exerted high bioavailability of catechin and associated with antiproliferative effects on breast cancer tissue [19] . Moreover, PEGylation of nanoparticles by incorporating or adsorbing of polyethylene glycol (PEG) chains on the nanoparticles' surface acts as a stabilizing factor, contributing greatly to their antitumor efficacy. PEGylated surfaces can protect nanocarriers from opsonization and reticuloendothelial system clearance by repelling plasma proteins. Therefore, allowing passive accumulation in tumor site by enhanced permeability and retention effect (EPR) [20] .
Different hybridization techniques have been utilized to formulate protein-lipid nanohybrids in order to deliver the bioactive agents across tumor sites [21] . In our laboratory, we have developed multicompartmental PEGylated celecoxib (CXB)-phospholipid complex bilayer-enveloping protamine nanocapsules (NCs) to codeliver letrozole (LTZ) and CXB against breast cancer. The NCs demonstrated effective antitumor activity at the level of breast cancer cells and animal models [22, 23] . According to our recent work, CAS MCs demonstrated a great potential for combined delivery of the fungal-derived monascus yellow pigments (MYPs) and RSV in breast cancer therapy [24] . Therefore, herein we investigate the influence of both passive and active targeting in enhancing their antitumor efficacy.
Therefore, in the current study, a mixture of natural antineoplastic bioactive principles (herbal RSV and fungal MYPs) was formulated in evergreen nanodelivery systems against breast cancer. First, we have developed FAconjugated CAS MCs (FA-CAS MCs) entrapping both RSV and MYPs as actively-targeted single-compartment nanocarriers, to enhance their uptake within breast cancer cells, via ligand-receptor-binding theory. In the second approach, we constructed multicompartmental nanovehicles where the hydrophobic MYPs were encapsulated into the hydrophobic core of CAS MCs and enveloped by a bilayer of PEGylated RSV-phytosomal complex as passively targeted nanodelivery system. The fabricated nanovehicles were thoroughly investigated in vitro and in vivo to prove the antitumor superiority of the multiple drug nanodelivery compared with the free drug combination.
Materials & methods

Materials
MNS and ANK were isolated from red mold rice in Microbial Biotechnology Laboratory, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt. RSV was purchased from Xi'an Natural Field Bio-Technique Co. Ltd (Xian Shaanxi, China). CAS from bovine milk, FA, DMSO, N,N'-diisopropylcarbodiimide (DIC), ethyl cyanoglyoxylate-2-oxime (Oxyma), triethylamine, tertiary butyl alcohol, acetic acid 99.9% technical grade, fetal bovine serum, 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT), mannitol, Triton X100, hematoxylin solution, eosin solution and Canada balsam were purchased from Sigma-Aldrich (MO, USA). Fat-free soybean phospholipid with 70% phosphatidylcholine (Lipoid S75) and [(N-carbonyl-methoxypolyethyleneglycol-2000)-1,2-distearoyl-sn-glecero-3-phosphoethanolamine, sodium salt] (PEG2000-DSPE) were kindly provided by Lipoid GmbH (Ludwigshafen, Germany). Tween 80 was purchased from ADWIC, El-Nasr Pharmaceutical Chemicals Co. (Cairo, Egypt). Acetonitrile HPLC grade was purchased from JT Baker (NJ, USA).
Preparation of FA-CAS
Conjugation of CAS and FA was performed via carbodiimide-coupling reaction [25, 26] . FA (0.088 g, 0.2 mmol) was dissolved in 10 ml DMSO. The reaction medium was rendered alkaline by addition of triethylamine (34 μl, ,000-14,000, SERVA, Germany) against DMSO for 24 h to allow equilibration. The free unconjugated FA was determined using a T80 UV/VIS spectrophotometer (PG Instruments Ltd, Lutterworth, UK). The absorbance (wavelength = 359 nm) of 24 h dialyzed DMSO was converted into an FA concentration by using a calibration curve constructed with standard FA solutions in DMSO [27] . Furthermore, this mixture was dialyzed against increasing gradients of DMSO:H 2 O and replaced every 6-8 h (100% DMSO, 90:10, 70:30, 50:50, 30:70, 10:90, 100% H 2 O) until complete elimination of DMSO and other reaction side products. After freeze-drying, FA-CAS conjugate was obtained as yellow powder.
The conjugation efficiency of FA reacted with CAS was determined by the indirect method. The unreacted free FA found in reaction dialysate was measured by T80 UV-visible (UV-Vis) spectrophotometer (PG Instruments Ltd) at 359 nm and calculated according to a preconstructed FA calibration curve. The UV spectra for FA, CAS MCs and FA-CAS MCs were recorded to confirm the conjugation reaction.
Preparation of FA-targeted RSV/MYP-loaded CAS MCs
To prepare FA-CAS MCs (F1), 10 mg RSV and 10 mg MYPs (5 mg MNS and 5 mg ANK) were dissolved in 95% ethanol and then added dropwise to 10 mg/ml aqueous FA-CAS solution (pH 7.4) under gentle magnetic stirring for 24 h. The prepared FA-CAS MCs (F1) was then lyophilized using 2.5%w/v mannitol as a cryoprotectant for 48 h in Cryodos-50 lyophilizer (Telstar Cryodos, Terrassa, Spain). The freeze-dried MCs were stored at 25
• C in a desiccator till further analysis [15, 28] .
Preparation of PEGPC-CAS MCs
To prepare MYPs-loaded CAS MCs, MYPs (5 mg MNS and 5 mg ANK) were dissolved in 95% ethanol and added dropwise to aqueous CAS solution (2 mg/ml, pH 7.4) under gentle magnetic stirring for 24 h. PEGylated phospholipid-RSV complex (PEGPC-CAS MCs, F2) was prepared via film-hydration method [29] . Briefly, a proper molar ratio (1:2) of RSV and phospholipids (Lipoid S75:DSPE-PEG 2000 [1:1 w/w]) was dissolved in 10 ml mixture of chloroform and methanol (1:1 v/v) and left overnight at room temperature with gentle stirring to allow the formation of RSV-PEGPC complex. A thin drug-phospholipid complex layer was prepared by the removing of organic solvents at a rotary evaporator (50 rpm and 45
• C). The flask was kept under vacuum for 1 h to ensure the evaporation of residual solvent. The PEG phospholipid-RSV complex was then used to envelop the MYP-loaded CAS MCs [30] . Thus, the thin film was hydrated for 1 h using the dispersion of previously prepared MYPs-loaded CAS MCs. The developed coloaded (PEGPC-CAS MCs, F2) was then lyophilized using 2.5% w/v mannitol for 2 days and left in the desiccator [31] . The composition of (FA-CAS MCs, F1) and (PEGPC-CAS MCs, F2) is illustrated in Table 1 .
Physicochemical characterization of the nanocarriers Entrapment efficiency (EE%) of both RSV and MYPs into CAS MCs was evaluated. An accurately weighed 20 mg of (FA-CAS MCs, F1) or (PEGPC-CAS MCs, F2) was mixed with 95% ethanol and metered to a constant volume under ultrasonication. Then, this solution was filtered using a membrane filter (0.45 μm), and then analyzed by HPLC. An HPLC method was developed for determination of RSV and MYPs simultaneously. An Agilent 1260 Infinity HPLC system with a quaternary pump, an autosampler, diode array detector and an Agilent Chemstation data processing system was used for the analysis. The HPLC analysis was carried out with an Agilent Zorbax Eclipse XDB C 18 reversed-phase column (250 × 4.6 mm, 5 μm size of particle) maintained at room temperature. For chromatographic elution, the rate of flow was 1 ml/min over the entire separation and the injection volume was 10 μl. A step gradient method was utilized for elution in which the mobile phase consisted initially of 50% acetonitrile and 50% acidified water (0.05% v/v acetic acid) for the first 5 min, followed by 80% acetonitrile and 20% acidified water for the next 12 min. Total run time was 17 min. RSV was detected at 306 nm at t R of 4.2 min, while MYPs (both MNS and ANK) were detected at 386 nm (at t R of 11.64 and 13.67 min, respectively). The encapsulation efficiency (%EE) and % drug loading (%DL) were calculated using the following equations:
The particle size (PS), polydispersity index (PDI) and zeta potential profiles of the nanocarriers were determined by dynamic light scattering (DLS) in a NanoZS/ZEN3600 Zetasizer (Malvern Instruments Ltd, Malvern, UK) with the sample previously diluted in ultrapure water. All of the DLS records were measured at 25
• C as triplet measurements. For the zeta potential measurement, nanocarrier suspension diluted in 1 mM KCl solution was placed in a universal folded capillary cell equipped with platinum electrodes. The zeta potential values were estimated from the average electrophoretic mobility, as analyzed by Laser Doppler Anemometry.
The in vitro release of RSV and MYPs from both CAS MCs was determined using the dialysis membrane method compared with free drug solution [32, 33] . An aliquot (2 ml) of micellar suspension containing determined drug amount (2 mg RSV, 1.2 mg MNS and 1.2 mg ANK) was transferred into dialysis bags (12-14 kDa MWCO VISKING dialysis tubing, SERVA, Germany). The bags were suspended in 200-ml phosphate-buffered saline (PBS), pH 7.4, with 0.2% w/v Tween 80, maintained in a water bath at (37 ± 0.5
• C, 100 rpm). After specific intervals, certain volume (2 ml) of the release medium containing the free drugs was transferred out and another equal volume of fresh release medium was added. All samples were run in triplicates and filtered using a syringe filter (0.45 μm), the released amount of RSV, MNS and ANK was analyzed by HPLC.
The physical stability of dual-loaded nanocarriers was evaluated according to time in both colloidal and solid state. Therefore, the micellar suspension was kept at 4
• C in sealed tubes. PS, PDI and zeta potential were monitored at several time points for 3 months. Moreover, the lyophilized dual drug-loaded MCs were re-evaluated for those parameters after 6-month storage in a desiccator at 25
• C.
Morphological analysis
Both types of CAS MCs were examined for their morphological characteristics using transmission electron microscopy (TEM; JEM-100 CX, JEOL, Tokoyo, Japan). A 50-fold diluted dispersion of F1 and F2 in distilled water was mounted on the carbon grid. The dispersion was stained with uranyl acetate solution for 1 min [34] . The excess stain was removed with a filter paper, and the sample was left for air drying.
Redispersibility testing
Suspension (2 ml) of both F1 and F2 containing mannitol (5% w/v) as cryoprotectant was transferred into 5-ml glass vials and frozen at -80 • C, then lyophilized for 24 h. The lyophilized nanoparticles (NPs) were kept in a desiccator at 25
• C. For reconstitution, a certain weight of lyophilized MCs cake was mixed with 2 ml of ultrapure water followed by gentle agitation. The reconstituted NPs were analyzed for PS, PDI and zeta potential. Moreover, the redispersibility index (RI, the ratio between PS after and before lyophilization, respectively) and the lyophilization yield were calculated for all formulations.
In vitro hemolysis
A screening assay of hemolytic activity was evaluated by measuring hemoglobin release from erythrocyte after incubation with (FA-CAS MCs, F1) and (PEGPC-CAS MCs, F2). Briefly, rat blood samples were collected into ethylenediaminetetraacetic acid containing test tubes, centrifuged and washed with saline. Red blood cells (RBCs) suspension was prepared by preparing tenfold dilution of RBCs with saline (1:9 v/v). Then, the RBCs suspension (2 ml) was incubated for 1 h with an equal volume of the micellar dispersion using two concentrations for each nanosystem (100 and 250 μg/ml), at 37
• C with gentle shaking. After sample centrifugation (3000 rpm for 5 min), the supernatant absorbance (A) was measured at 545 nm using UV-Vis spectrophotometry. Both negative and positive control solutions were prepared by addition 2-ml RBC suspension to the same volume of saline (0% lysis) or 1% Triton X100 (100% lysis) for negative and positive controls, respectively. The hemolytic rates of the samples were calculated according to the following equation [35] .
Hemolytic rate
A t , A nc and A pc : absorbance value of test sample, negative and positive controls, respectively.
In vitro cytotoxicity study
This study was achieved using human breast adenocarcinoma MCF-7 cell line (purchased from American Type Culture Collection, ATCC, USA). The cells were kept in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum in a CO 2 incubator (5% CO 2 at 37 • C). Cells were seeded at a density of 5 × 10 3 /well in a 96-well plate containing 100 μl of DMEM and allowed to adhere to the plate overnight. The cytotoxicity of the free drugs and drug-loaded CAS MCs (F1 and F2) on MCF-7 cells was assessed by the MTT assay [36] . Therefore, the medium was substituted by fresh medium containing various concentrations of the drugs either as solution or encapsulated in MCs and incubated for another 24 h. Then, 100 μl of MTT solution (0.5 mg/ml in DMEM) was added to replace the culture medium and incubated for further 4 h at 37
• C under the dark. The supernatant was removed by centrifugation at 2000 rpm for 10 min, and then the elaborated MTT-formazan crystals were dissolved by addition of 100 μl of DMSO to the wells and maintained for 15 min under agitation. Absorbance of the converted dye was recorded at a wavelength of 570 nm using a microplate reader (Model 550, Bio-Rad, CA, USA). The cell viability was expressed as percentage of the untreated control wells. The IC 50 values were determined using Origin 8.0 (Origin Lab, MA, USA) depending on the fitted data.
In vivo study Animals & developing of tumor model
In this study, female BALB/C mice (7-8 weeks, 25 ± 5 g) were housed in stainless-steel mesh cages, under standard temperature, illumination, humidity, food and water supply. Female BALB/c mice were subcutaneously inoculated into the left side of the mammary fat pad with approximately 10 7 of EAT cells suspended in PBS (National Institute of Cancer, Egypt). EAT cells were obtained from the ascitic fluid of inoculated BALB/c mice with 8-10 days old ascitic tumor [37] . Tumor growth was checked daily until its volume reached 100 mm 3 . Tumor volume was assessed based on tumor's perpendicular diameters using the following equation:
Tumor volume / JI minor axis X major axis
In vivo antitumor efficacy Animals were categorized into eight groups (eight mice/group). These groups included positive control (untreated EAT-inoculated mice), negative control (healthy mice receiving saline), blank FA-CAS MCs, free MYPs, free RSV, free combined MYPs-RSV cosolvent composed of DMSO:PEG400:saline (0.5:3.5:6 v/v/v), FA-CAS MCs, F1 and PEGPC-CAS MCs, F2-treated groups. The tumor-bearing mice were injected in the tail vein with the free drugs or MCs equivalent to 5 mg/kg per day of RSV, for consecutive 3 weeks. Each mouse was tail-marked and followed individually throughout the whole experiment. To avoid the hypoglycemic effect of the MYPs, all groups received 1 ml of 10% w/v dextrose by oral route prior to each treatment dose. All the surviving mice were sacrificed after 21 days by cervical dislocation. The excised tumors were divided into two parts; one part was used for assessment of tumor biomarkers and the second part was used for histopathological studies. The tumor volume, the weight of the tumors after excision and percentage body weight change for all groups throughout the treatment course were determined.
Tumor growth biomarkers
Homogenization of the excised tumors in cold PBS was performed, a final 40% tumor homogenate was divided into five fractions for quantitative determination of tumor biomarkers. Aromatase expression level was quantified using 'AROBioAssay ELISA Kit' (US Biological Life Sciences, USA). Angiogenesis was expressed in the term of VEGF level using 'VEGF ELISA Kit' (RayBio Tech Inc., USA) and Cyclin D1 (Rat Cyclin-D1 ELISA Kit, EIAab™). Apoptosis was determined according to the level of tissue caspase 3 using 'Caspase 3 (Casp-3) ELISA Kit' (WKEA Med Supplies Co., USA). NF-κB was determined using 'Bio Source NF-κB ELISA kit' (BioSource International Inc., USA). All the markers were quantified based on the manufacturing protocol.
Histopathological study Preservation and fixation of the tumor samples were performed using neutral formalin (10%) for 24 h. Tissue sections (5 μm thick) were immersed in distilled water, stained with hematoxylin for 5 min and eosin for 2 min, dehydrated in alcohol and mounted in Canada balsam prior to examination by microscope. Necrosis scores are provided in the Supplementary Materials section.
Statistical analysis IBM SPSS software package (version 20) was used to analyze the in vivo results. Analysis of Variance test and Tukey's
Multiple Comparison test were utilized for pair-wise statistical comparisons between the investigated groups. Results significance was judged at the 5% level.
Results & discussion
Physicochemical characterization of prepared MCs
As an active tumor-targeting approach, FA was coupled to CAS via simple carbodimide formation. The carboxylic group of FA was activated in the presence of DIC and Oxyma into active ester intermediate. This intermediate has reduced racemization level and suppresses the undesirable side reactions [38] . For further structural investigations, UV spectra of FA, CAS MCs and FA-CAS MCs conjugates were recorded. As shown in Figure 1 , FA spectrum showed its characteristic peaks at 258, 285 and 365 nm. On the other hand, spectrum of CAS MCs exhibited only the characteristic 280-nm protein peak with no peaks in the 360-nm region. Interestingly, the spectrum of our developed FA-CAS MCs showed peaks at 356, 288 and 367 nm corresponding to the folate moiety. This confirmed the chemical conjugation of folate to CAS elaborating FA-CAS conjugate [39] .
The lyophilized FA-CAS conjugate was obtained as deep yellow powder with conjugation efficiency of 97% calculated by the calibration curve method. Depending on intrinsic amphiphilic characteristic of CAS, the hydrophobic drugs could be entrapped within CAS hydrophobic interior. Consequently, in our work, both hydrophobic MYPs and RSV were encapsulated within the lipophilic cargo of FA-CAS MCs. Blank FA-CAS MCs investigated a PS of (124 ± 3.0 nm), which increased to 137 ± 5.0 nm after RSV + MYPs dual loading (Table 1 & Figure 2A ). The PS increment confirmed successful drug encapsulation. FA-CAS MCs, F1 exhibited negative zeta potential (-21 ± 1.9 mV) reflecting a good colloidal stability (Table 1) . These results are in accordance with Teng et al.'s finding, who synthesized curcumin-encapsulated FA-conjugated soy protein nanoparticles with zeta potential ranged from -36 to -42 mV [40] . RSV, MNS and ANK were efficiently encapsulated into FA-CAS MCs with %EE of 86.0, 86.3 and 85.82% w/w, respectively.
In another approach, coating of CAS MCs with PEGylated phytosomal RSV complex layer produced a compact multireservoir nanosystem that allows passive accumulation in the tumorous site via EPR mechanism. Successful RSV complex formation was confirmed by disappearance of its melting endothermic peak in the complex thermogram (mentioned in Supplementary material section). The hydrophilic interaction between Î-CAS-enriched surface and polar molecules of the phospholipid bilayer represented a stabilizing factor for this nanovehicle. PEGPC-CAS MCs, F2 exhibited larger PS (272.6 ± 7.0 nm) in relative to (FA-CAS MCs, F1), (Figure 2A mesoporous silica with larger PS of 360 nm have been exerted extraordinarily stability and protection against being captured in the spleen [41] . Compared with FA-CAS MCs, (PEGPC-CAS MCs, F2) demonstrated higher %EE of RSV (99.0%) against 86.0% for (FA-CAS MCs, F1). This could be explained by the highly immersion of RSV in the lipidic bilayer augmented by successful complex formation of RSV with phospholipids via both hydrogen bond and van der Waals bond. Similar entrapment of genistein (97.9%) within the phospholipid bilayer enveloping poly(lactic-co-glycolic) (PLGA)-paclitaxel NCs was reported [30] . Both lipophilic MNS and ANK were highly encapsulated in both types of MCs may be due to their high affinity to the hydrophobic micellar core.
Under TEM, both FA-CAS MCs and PEGPC-CAS MCs were demonstrated uniform size and smooth surface with no aggregation confirming high colloidal stability. PS reported by TEM was smaller than that reported by DLS (108.2 ± 11.10 and 129.97 ± 9.1 nm for FA-CAS MCs [F1] and PEGPC-CAS [F2], respectively) due to particle shrinkage during the drying step in TEM analysis instead of the presence of the hydrodynamic layer around the MCs in the colloidal form [33] . Interestingly, the core-shell-type structure of PEGPC-CAS MCs was demonstrated with the PEGylated lipid bilayer around 24.76 nm (Figure 2C & D) .
In vitro release
Commonly, in all drug-release experiments, the release pattern of drugs from the developed nanoformulations was compared with free drug solution to detect the capacity of the nanocarriers to provide sustained drug release compared with fast release from solution. This sustained release profile is required to prevent the premature drug release into systemic circulation and keep it released at tumor sites. Both folate-conjugated and PEGylated CAS MCs exhibited a biphasic-release pattern of RSV, MNS and ANK showing initial burst release followed by sustained released profile ( Figure 3A & B) . After 4 h, about 43.6% of RSV was released from PEGPC-CAS MCs compared with only 12.78% from FA-CAS MCs. This can be explained by influence of both PEGylation [42] and phospholipid complex formation on RSV solubility and release behavior. Bioavailability and clinical application of another botanical polyphenols (Curcumin, Silymarin and Green Tea Extracts) were improved substantially in the form of phytosomes via phospholipids-complex formation [43] . After 24 h, about 89.3 and 98.8% of RSV was released from FA-CAS MCs (F1) and PEGPC-CAS MCs (F2), respectively. In comparison, 100% free RSV was released from its solution within 2 h. Regarding the release of MNS, the PEGylated phospholipid bilayer was observed to reduce its burst release after 4 h from 49.9% for FA-CAS MCs (F1) to 28.5% for PEGPC-CAS (F2) followed by a slow release of the remaining drug up to 90.0 and 73.7%, respectively, after 24 h. MNS released from the micellar hydrophobic core has to diffuse through an extra barrier, as phospholipid bilayer is acting as a molecular fence that leads to retain the drug molecules in the internal core. Controlled and sustained drug-release profiles of docetaxel was observed from PLGA-lecithin-PEG NPs where the degree of lipid covering influenced its drug release [44] . With the same manner, similar release behavior was previously reported for letrozole where PEGylated protamine NCs effectively reduced the initial burst release of LTZ release after 4 h compared with PRM-NCs and HA-NCs [22] .
A more powerful prolonged release pattern of ANK was reported from both folate and PEGylated micellar systems. This behavior may be attributed to the higher hydrophobicity of ANK compared with MNS resulting in higher affinity to the hydrophobic cargo of MCs. Therefore, about 70.6 and 60.6% of ANK was released from FA-CAS MCs (F1) and PEGPC-CAS (F2) after 24 h, respectively.
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Physical stability & redispersibility
The storage stability of our prepared nanoformulae in both colloidal and solid state was evaluated. FA-CAS MCs, F1 demonstrated a gradual PS increase when stored in colloidal form at 4
• C (140.1 ± 2.1 and 186.2 ± 1.3 nm after 2 and 4 weeks, respectively) compared with initial size (137.9 ± 3.0 nm). However, after 3 months, FA-CAS MCs showed a dramatic size increase reaching 505 ± 4.1 nm, this observation may be result of origination of minor alterations in protein secondary structure as the FA-CAS interaction might affected the MCs colloidal stability on the long run [45] . Regarding to surface charge, approximately no obvious change in zeta potential compared with initial measurement (-25 ± 2.0 mV). In parallel, the physical stability of CAS MCs was improved via RSV-PEGPC bilayer enveloping. After 3 months of PEGPC-CAS MCs (F2) colloidal storage, mean PS became slightly larger in relative to the initial measurements (300 ± 5.0 nm after 3 months) versus (270 ± 10.63 nm starting measurement). Moreover, no change in zeta potential was observed, see Figure 3C . Generally, due to steric stabilization by the PEGylated shell, increased stability may have been envisaged as reported for other PEGylated particle types [22] .
Potential pharmaceutical applicability of these NPs needs scalable processes for the storage of larger batches of NPs. However, the nanosystems were evaluated according to their solid-state stability using freeze-dried powdered form, mannitol (2.5% w/v) was used to enhance the drying and redispersibility of lyophilized nanocarriers. These additives are commonly added in order to protect the nanoparticles from the stress of freezing (cryoprotectant) or drying (lyo-protectant) [46] . The lyophilized form of both prepared nanosystems investigated excellent stability with no change in PS (139 ± 5.1 and 265.2 ± 7.3 nm for FA-CAS MCs, F1 and PEGPC-CAS, F2, respectively) after 6 months storage at room temperature in the desiccator compared with the initial (137 ± 5.0 and 272.6 ± 7.0 nm for FA-CAS MCs, F1 and PEGPC-CAS, F2, respectively). Both formulae were freely redispersible in aqueous medium as mannitol allows for recovery of (140 ± 6.2 and 270.4 Table 2 . Therefore, storage of MCs in a lyophilized form rather than a liquid dispersion was found to be an effective to induce the stability of MCs and preserve their size characteristics. Similar observation was reported when PLGA-lecithin-PEG NPs were prepared in freeze dried form using (10% w/v) sucrose as a cryoprotectant and allows for recovery of 87.0 ± 0.6 nm NPs versus the original 64.5 ± 0.5 nm diameters [44] .
In vitro hemolysis test
Hemolysis in vivo can cause anemia, jaundice and other pathological symptoms, so acceptable hemolytic activity of NPs (<5%) represented a crucial factor for any parenteral delivery system [47] . Two concentrations of each nanosystem were evaluated in this study (100 and 250 μg/ml). At a concentration of 250 μg/ml, the percentage hemolysis induced by FA-CAS MCs, F1 and PEGPC-CAS MCs, F2 was 1.3 and 1.8%, respectively. At lower concentration of 100 μg/ml, the percentage hemolysis of folate-targeted MCs was obviously decreased to 0.22% while the PEGylated nanosystem still had approximately the same value (1.7%), see Figure 4A & B. The lower hemolysis activity of folate nanosystem compared with PEGylated one may be attributed to the protective effect of highly hydrated k-CAS hairs, which act as a protective coat on the surface of CAS MCs along with folate moieties that hinder their interaction with RBCs. Furthermore, the negativity of our nanosystems' surface possess less damaging effect on the negatively charged RBCs outer membrane due to the repulsion effect and hence longer blood circulation and lower opsonization [48] . Our results are in agreement with the finding of Li et al., who reported the hemocompatibility of mitomycin-soybean phosphatidylcholine complex-loaded PEG lipid-PLA hybrid nanoparticles with folate functionalization where no significant hemolytic effects were observed even at the elevated concentration [49] . Similarly, it should be kept in mind that PEG steric barrier was conceived with the idea of preventing the absorption of lysozymes and reducing the interaction with RBCs. Zhu et al. suggested that PEGylation of chitosan NPs could be a successful approach for reduction of NPs hemolytic activity [50] .
In vitro cytotoxicity Clearly, both developed MCs (F1 and F2) were significantly effective in inhibiting growth of MCF-7 cells at the concentration range of (0-50 μg/ml). In relative to free drug combination, RSV + MYPs (IC 50 = 37.9 μg/ml), FA-CAS MCs, F1 and PEGPC-CAS MCs, F2 showed IC 50 of 20.3 and 20.5 μg/ml, respectively, after 24 h, reflecting their superior antineoplastic efficiency (p < 0.05*), (Figure 4C & D) . At higher concentration (50 μg/ml) of the drug, there was no change in percentage survival index for F2 and free RSV + MYPs, which may be due to the effect of release pattern and the difference in cellular uptake mechanisms. Blank nanocarriers demonstrated very little toxicity to MCF-7 cells due to the change of the tumorous environment by EPR (viability was >80% after 24 h). The inhibition of MCF-7 cells by FA-CAS MCs, F1 can be ascribed to rapid incorporation into MCF-7 cells via the specific ligand-receptor (folate-folate receptor) interaction. This result is in agreement with the previously reported higher uptake of covalent-conjugated FA-HSA NPs into cancer cells [51] . Recently, Hao et al. reported the superior cytotoxicity of folate-targeted RSV-loaded Pluronic/TPGS- mixed MCs (IC 50 = 27.89 μg/ml) against folate receptor-overexpressing MCF-7 cells compared with free RSV (137.58 μg/ml) after 48 h [52] . Furthermore, the structure resemblance of phospholipid bilayer to the lipid content of the mammalian cellular membrane can increase membrane penetration. In our laboratory, PEGylated protamine NCs enhanced the cytotoxicity potency of LTZ-CXB combination compared with free combined drug solution against MCF-7 (IC 50 = 14.4 μg/ml) [22] . 3 ) during the same course of treatment regimen indicated good combination selection. Interestingly, antineoplastic activity was enhanced via coincorporation of our novel cocktail into the micellar systems [15] . At the end of the treatment course, PEGylated MCs were superior to folate-conjugated MCs as evidenced by higher tumor regression (694.3 and 590.3 mm 3 ) for FA-CAS MCs, F1 and PEGPC-CAS, F2, respectively, Figure 5A .
In vivo assay
The weight of the excited tumors was also determined for each group. PEGylated-and folate-treated groups demonstrated obvious reduction in average tumor weight compared with other groups ensuring excellent anti neoplastic effect of our nanosystems (data not shown). The nanosize, folate-conjugation and PEG coating help enhancing the permeation of CAS MCs across the cellular membrane. Geng et al. demonstrated the best tumor growth suppression effect of RSV-loaded RGD-conjugated HSA nanoparticles via a PEG bridge by virtue of the improved RSV biocompatibility and prolonged circulation [53] .
Although RSV seems to have a negligible toxicity limit [54] , the antidiabetic effect of both RSV [55] and MYPs [56] can explain the higher percentage body weight loss in free drugs combination-treated groups (16.00%) recorded at the end of the study in relative to coloaded micellar systems. Interestingly, FA-CAS MCs, F1-treated group demonstrated reduced body weight loss to 5.04%, while PEGPC-CAS MCs (F2)-treated group showed an increase rather than decrease in body weight by 2.7% confirming the efficiency of the PEGylation strategy in toxicity reduction ( Figure 5B ). This result may be attributed to the elevated systemic toxicity of chemotherapeutic drugs in their free state, while utilizing nanovehicle as homing devices for these drugs could likely protected the mice from their toxic effects.
Determination of tumor growth biomarkers
Our selection of naturally chemosensitizers of RSV and MYPs could exert synergistic effects on aromatase level inhibition in cancer cells as RSV is a potential inhibitor in the aromatase synthesis pathway at the enzyme and mRNA levels [57] . In addition, docking studies presented the most constructive binding mode of MNS and ANK to aromatase exposed the capability of these natural biopigments to treat breast cancer via aromatase targeting [10] . Regarding the aromatase level, a comparable pattern of response was observed where all treated groups demonstrated lower aromatase levels in comparison to the untreated positive control, which showed an aromatase level of 77.14 ng/mg tissue protein. The significant aromatase level reduction (p < 0.05*) was recorded for both (FA-CAS MCs, F1) and (PEGPC-CAS MCs, F2) treated groups corresponding to 6.14 and 7.89 ng/mg tissue protein, respectively ( Figure 5C ). The superiority of the coloaded nanovehicles over the free RSV + MYPs cosolvent could be directly related to the enhanced cellular permeation via both PEGylation and folate receptor targeting of dual-loaded nanostructured delivery system reflected on the reduction of tumor development and aromatase inhibition with subsequent reduction of de novo estrogen synthesis.
VEGF is overexpressed in almost all cancer types, however, no VEGF expression in normal tissues. Although there was no direct information which explains the effect of MYPs on tumor angiogenesis, we supposed a positive relationship between MYPs anti-inflammatory effect and cancer metastasis control. Both folate and PEGylated micellar systems were significantly (p < 0.05 * ) reduced VEGF level in comparison with the positive control and free drugs-treated groups (6.44 and 9.95 ng/mg tissue protein, for (FA-CAS MCs, F1) and (PEGPC-CAS MCs, F2), respectively ( Figure 5D ). That is because specific receptor-mediated interaction enhances NPs uptake into the targeted cells.
Cyclin D1 is a marker of proliferation that regulates the cell cycle essentially in G1 phase. It is a candidate proto oncogene contributed in pathogenesis of several human tumors with high-expression level, especially in breast cancer. With the same manner, both folate and PEGylated formulae were significantly (p < 0.05 * ) reduced cyclin D1 level by 5.4-and 4.94-folds, respectively, when compared with free drug combination-treated groups ( Figure 6A ).
NF-κB has turned out to be a substantial therapeutic target in cancer remedy as it shown to be activated in cancer tissues. Incorrect regulation of NF-κB has been linked to carcinogenesis, inflammatory and autoimmune diseases. These investigated measurements could confirm the capacity of our novel fabricated nanovehicle to exert a significant reduction effect on NF-κB level (p < 0.05*). All treated groups exhibited a significant lower NF-κB level compared with positive control and free drug cosolvent confirming our great success in the selection of this novel drugs cocktail (p < 0.05*). FA-CAS MCs (F1) and PEGPC-CAS (F2) highly reduced NF-κB level by 8.22-and 5.68-folds, respectively, when compared with free RSV + MYPs cosolvent-treated group ( Figure 6B ).
In addition, the apoptotic rate in mice tumor tissue was evaluated by measuring caspase-3 level as a marker of apoptosis. It was reported that both RSV and MYPs could induce cellular apoptosis through various points in the apoptotic pathway. In our work, all treated groups displayed elevated apoptotic effect with a significant higher caspase-3 level (p < 0.05*) compared with untreated positive control group. FA-CAS MCs (F1) and PEGPC-CAS (F2) increased caspase-3 level by 3.59-and 2.9-folds, respectively, when compared with free RSV + MYPs-treated group ( Figure 6C ). From these outcomes, both FA-CAS MCs (F1) and PEGPC-CAS MCs (F2) treated groups demonstrated a significant reduction (p < 0.05*) for all measured tumor biomarkers level compared with untreated positive control and free drugs combination-treated group. Upon comparing the total antitumor efficacy of FA-CAS MCs (F1) and PEGPC-CAS MCs (F2) to each other, we excluded that although (FA-CAS MCs, F1) exerted slightly (nonsignificant) higher effect on reducing the tumor growth biomarkers levels compared with PEGPC-CAS MCs (F2), a slight increase in the average tumor volume of F1-treated group (694.3 mm 3 ) was recorded after 3 weeks compared with that measurement of F2-treated group (590.3 mm 3 ). This observation could be explained as a result of great necrotic damage of cancer cells and neighboring tissues that stimulate an inflammatory response for healing [58] .
Histopathological study
Additional evidence of the induced anticancer efficiency of the RSV-MNS-ANK-loaded MCs was analyzed by histological examination. The abundant tumor cells were investigated in the positive control group. On the contrary, the extensive dead cells without nuclei were reported in the tumor treated with FA-CAS MCs (F1) and PEGPC-CAS MCs (F2) as both yielded greater capacity in inducing the cell apoptosis/death and reducing the cell proliferation, which was explained by higher scoring of necrosis (2.64 ± 0.05 and 2.96 ± 0.07, respectively) compared with free combination-treated groups (2.08 ± 0.03%). Our investigation can be explained by the ability of negatively charged nanodelivery system for cellular internalization, which is believed to occur through nonspecific accumulation of MCs on the plasma membrane's cationic sites [59] . Moreover, the folate targeting and PEGylated properties greatly improved the therapeutic activity of the loaded NPs because of the higher clustering at the tumor site and the greater cellular uptake by the tumor cells ( Figure 6D ). Our results are in agreement to the findings of Martinez et al., who showed the most quiescent and disorganized structures of breast cancer xenograft tumors after treatment of tamoxifen-loaded folate-targeted BSA nanoparticles [60] .
According to the abovementioned results, there is a clear evidence on the enhancement of antineoplastic activity of RSV in multiple-step strategy including: Coadministration of monascus biopigments with RSV can enhance the antitumor efficacy of both drugs through several mechanistic pathways as confirmed by synergistic reduction of tumor biomarkers. Dual encapsulation of RSV and MYPs combination into CAS micellar nanosystems can provide full protection of both drugs, sustainable drug release and improved cell membrane penetration potency. Preparation of novel folate-targeted coloaded RSV/MYPs CAS MCs in this step dual utility of both ultrasmall size and ligand-receptor binding of nanodelivery system were achieved. In addition to nanosize-mediated EPR effect, folatereceptor targetability has been exploited since FA receptors are highly abundant on the surface of metabolically active breast cancer cells, resulting in additional specific cellular internalization and extra-antineoplastic activity of both. Envelopment of MYPs-loaded CAS MCs within PEGylated phytosomal RSV bilayer to evade opsonization thus avoiding reticuloendothelial system uptake leading to prolonged systemic circulation as well as enhanced release of RSV via complexation with phospholipids. The improved colloidal stabilization of CAS MCs via steric and electrostatic effects, and the enhanced permeation through cancer cell membranes may be both mediated by the unique phosphatidylcholine composition.
Conclusion
A novel combination rationale of RSV + MYPs was selected based on their basic mechanistic pathways. We fabricated two novel nanodelivery systems including RSV-MYPs dual-loaded FA-CAS MCs to enable tumor targeting, in parallel with PEGPC-CAS MCs as passively nanoparadigm for breast cancer therapy. Both micellar nanosystems presented an appropriate PS and zeta potential, a good solid-state stability, high EE and controlled drug release, which led to improved drug efficiency and reduced toxicity in the experimental animals. Both nanosystems exhibited highly selective tumor accumulation and greatly superior therapeutic efficiency in vivo confirmed by their potential effect on tumor volume, tumor growth biomarkers including aromatase, VEGF, CD-1, NF-κB, Caspase-3 as well as histopathological studies. Both FA-CAS MCs and PEGPC-CAS MCs had comparable antineoplastic activity. Therefore, we suggested that both were robust and attractive drug delivery systems for effective chemotherapy against breast cancer.
Summary points
• A novel combination of herbal and microbial-derived antineoplastic drugs (resveratrol [RSV]/monascus yellow pigments [MYPs]) was selected based on their mechanistic pathways for breast cancer therapy.
• Active-targeted casein micelles (CAS MCs) were developed by carbodiimide coupling of folate to enhance their internalization into breast cancer cells via receptor-mediated endocytosis.
• Passively targeted multicompartmental nanocarriers were developed by enveloping MYPs-loaded CAS MCs within PEGylated phospholipid-RSV complex bilayer prepared via thin film hydration.
• Both micellar types exhibited acceptable physicochemical properties, good stability profile and superior cytotoxicity to breast cancer cells compared with free MYPs/RSV combination, which can be attributed to prolonged circulation, enhanced cellular internalization resulting in higher drug accumulation and improved antitumor efficacy.
• Both MCs demonstrated powerful and comparable anticancer activity in Ehrlich Ascitis mammary tumor mice model revealed as significant reduction of tumor volume and weight, suppression of aromatase, VEGF, CD-1, NF-κB and elevation of Caspase-3, augmented by histopathological studies.
• The dual drug-loaded micellar systems demonstrated reduced body weight loss of treated animals compared with the higher body weight loss in free drug combination-treated groups, thus confirming the ability of MCs to reduce the drug toxicity.
• Both folate-targeted CAS MCs and PEGylated RSV-phospholipid complex bilayer enveloping CAS MCs were supposed to be potential nanodelivery systems for targeted breast cancer therapy.
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